Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease.
Marité García-LlanoIvonne Pedroso-IbáñezLilia Morales ChaconTeresita Rodríguez-ObayaLeslie Pérez-RuizIliana Sosa-TestéDaniel Amaro-GonzálezMaria Luisa BringasPublished in: MEDICC review (2021)
Nasally administered NeuroEPO for five weeks in patients with Parkinson disease stages 1 and 2 on Hoehn & Yahr Scale is well tolerated.
Keyphrases